Date: 16th April 2015

Minutes: Final

Guideline Development Group Meeting 14 Type 2 Diabetes
Place: Floor 24, Red Rooms, City Tower, Piccadilly Plaza, Manchester

Present: Damien Longson (Chair)
Ian Lewin (IL)
Sailesh Sankar (SS)
Jonathan Roddick (JR)
Anne Bentley (AB)
Natasha Jacques (NJ)
Yvonne Johns (YJ)
Natasha Marsland (NM)

Apologies: Amanda Adler (AA)
Prunella Neale (PN)
Andrew Farmer (AFr)
Maria Cowell (MC)

In attendance:

NICE Staff:
Sharlene Ting (ST)
Stephanie Mills (SM)
Steven Ward (SWard)
Hugh McGuire (HM)
Clifford Middleton (CM)
Susan Ellerby (SE)
Sue Spiers (SS)
Sarah Palombella (SP)

Observers:
1. DL welcomed the group to the 14th meeting of this guideline development group (GDG). This meeting was set up to continue discussion on the pharmacological management section in the type 2 diabetes guideline. Apologies were received from AA, AF, MC and PN. All committee members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all present.

2. ST briefly re-capped on feedback on the recommendations for second intensification of pharmacological therapy and asked the committee to think about how these recommendations may change. The committee discussed the role of GLP-1 mimetics, the ordering of the recommendations, stopping rules for therapy and then went on to discuss the wording of the recommendations on insulin therapy in people with type 2 diabetes. Subsequently, some changes were made to the wording of the recommendations.

3. Following lunch, the committee were asked to look at the revised algorithm for pharmacological management. The committee approved the new layout and discussed escalation points for treatment.

4. IL presented feedback from the Diabetes Oversight Group (DOG) meeting for all areas of the type 2 diabetes guideline except for pharmacological management. During this session DL had to leave but SS took over the chairing role of the meeting. The committee debated the suggestions but concluded that the wording of most of the recommendations was justified and that the internal development team should ensure this justification is captured in the linking evidence to recommendations tables.

5. SM presented the next steps advising the committee of when the guideline would be sent to them for their comments, the NICE policy on declarations of interest, expenses and the publication date for the suite of diabetes guidance. SM thanked the group for their hard work and commitment and confirmed that any further queries in relation to the guideline or potential changes to timelines would be communicated to the group. SS also thanked the committee for their contributions and wished everyone a safe return journey.

**Date, time and venue of the next meeting**

No further meetings